Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug conjugate (ADC ...

Federal funds for 122 railway projects were recently awarded through the FRA’s Consolidated Rail Infrastructure and Safety Improvements Program for fiscal years 2023 and 2024. Of the $2.4 ...

It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...

Additionally, AbbVie's oncology segment benefited from solid sales of Venclexta and the newly acquired Elahere, reinforcing positive investor sentiment. For the current fiscal year, ending in ...

Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Elahere is part of a class of drugs known as an antibody-drug conjugate (ADC). It works by attaching to FRα in the cancer cells. This attachment blocks FRα from receiving signals that tell the cancer ...

patients who may benefit from ELAHERE ; LightCycler PRO System, a qPCR system designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories; and cobas pulse, a ...

ADC driver amplifiers perform many important functions, including buffering, amplitude scaling, single-ended-to-differential and differential-to-single-ended conversion, common-mode offset adjustment, ...